What do I do next?"

Yes, these are all really great questions, and I think we actually hit on a lot of those, um, um, during our webinar about reapplication.

Um, uh, I did present some data on reapplicants actually at AAO and AAO-PO, um, in the last one to two years, where, uh, if you look at about three hundred reapplicants total, the match rate is about 50% or so.

And so that does tell me that there are many programs, um, for whom the doors are not closed on reapplicants.

The key is in sort of distinguishing those who succeed from those who don't.

Um, and I feel like through, you know, personal experience, I've been, uh, running a research fellowship now for about seven years or so, um, and of the people who succeed, um, I usually look for, you know, applicants who have a lot of potential, but who maybe didn't have access to the right mentors or, you know, a school without a home program, kind of fell through the cracks.

People who are able to, um, do the soul searching that Chris talked about, being able to self-reflect and be honest with yourself, um, and figure out what you can do to improve.

What do you tell someone when they're like, "What do I do in terms of the timing, or should I do intern year?"

Um, so when you're talking about getting brain samples, number of patients, number of brains, how much tissue are you getting? Are these from, um, politely living people? Are these the recently deceased? I, I don't know, and I just thought I'd ask for everyone out there who's curious.

So they're from, uh, deceased patients.

This is why it's actually it's so hard is because, you know, in cancer, the problem of how do we actually find the right patient and match them to the right drug has been partly solved because you can actually take a tumor, right, from a living person.

Um, you can profile it and analyze it, and then you can match it to the therapy that you want that patient to be on.

In the brain, you know, um, you can't take a brain from a living person, right, in neurological disease, and so you can only take it from autopsy patients.

And so that is what we have done is that we've partnered with more than 24 different tissue banks, hospitals, academic centers across the world that have thousands and thousands of patient brains from people that have passed away from disease and donated their bodies for research.

And then we've built an end-to-end infrastructure that can actually ingest these samples, quality control them, dissect them, um, for data consistency, quality, and traceability.

Um, I think people have been seeing, I've seen coding agents do so well, and say, "Hey, why aren't we there with, um, drug discovery and health yet?" So if you could take a, like a, like a 50% confidence interval guess about where both Verge is and other companies in the bio-AI space, where are we in five years? What have we unlocked, and are we gonna feel that difference in our kind of lived medical reality?